Tumor necrosis factor (TNF) receptor-associated factor 2 (TRAF2) is an adaptor protein that modulates the activation of the c-Jun NH 2 terminal kinase (JNK)/c-Jun and IKB kinase (IKK)/nuclear factor-KB (NF-KB) signaling cascades in response to TNFA stimulation. Although many serine/threonine kinases have been implicated in TNFA-induced IKK activation and NF-KB-dependent gene expression, most of them do not directly activate IKK. Here, we report that protein kinase CZ phosphorylates TRAF2 at Ser 55 , within the RING domain of the protein, after TNFA stimulation. Although this phosphorylation event has a minimal effect on induction of the immediate/transient phase of IKK and JNK activation by TNFA, it promotes the secondary/prolonged phase of IKK activation and inhibits that of JNK. Importantly, constitutive TRAF2 phosphorylation increased both basal and inducible NF-KB activation and rendered Ha-Ras-V12-transformed cells resistant to stress-induced apoptosis. Moreover, TRAF2 was found to be constitutively phosphorylated in some malignant cancer cell lines and Hodgkin's lymphoma. These results reveal a new level of complexity in TNFA-induced IKK activation modulated by TRAF2 phosphorylation and suggest that TRAF2 phosphorylation is one of the events that are responsible for elevated basal NF-KB activity in certain human cancers.
Introduction
The tumor necrosis factor (TNF) receptor (TNFR)-associated factor (TRAF) family consists of six members and is characterized by a highly conserved TRAF domain at the protein COOH terminus. With the exception of TRAF1, the TRAFs contain an NH 2 terminal RING finger domain followed by five or seven zinc-finger motifs (1, 2) . Whereas the TRAF domain is required for interactions with the receptors and effectors of the signaling pathway, the RING domain is believed to be essential for activation of downstream signaling pathways (2) . TRAF2 is a prototypical member of the TRAF family and regulates signals that emanate from several members of the TNFR superfamily, resulting in the sequential activation of mitogen-activated protein kinase (MAPK) kinase (MAPKK) kinase (e.g., MEKK1/3), MAPKK (e.g., MKK4/7), and MAPK [e.g., c-Jun NH 2 terminal kinase (JNK)] and in the activation of transforming growth factor-h-activated kinase 1, receptor interacting protein 1 (RIP1), and InB kinase (IKK).
MAPK and IKK activate activator protein-1 (AP-1; e.g., c-Jun/ activating transcription factor 2) and nuclear factor-nB (NF-nB) transcription factors. Activated AP-1 and NF-nB, in turn, induce the expression of genes involved in inflammation, immune response, cell proliferation, and cell differentiation, as well as genes that act to suppress death receptor-induced and stress-induced apoptosis (1, 3) . Gene knockout and transgenic studies have firmly established that the activation of the NF-nB pathway is essential for cancer cell progression and metastasis (4) (5) (6) (7) . In addition, many types of cancer cells exhibit elevated basal NF-nB activity and inhibition of NF-nB sensitizes cancer cells to stress-induced apoptosis (4, 6, 7) . However, the mechanism underlying the constitutive activation of NF-nB in human tumors is still not fully understood (4, 6, 7) .
Knockout of TRAF2 impairs TNFa-induced activation of JNK, but not of IKK (8) . Tada and colleagues have reported that TRAF2 and TRAF5 double-knockout (TRAF2/5 DKO) mouse embryonic fibroblasts (MEF) exhibit an almost complete defect in TNFainduced IKK activation (9) , suggesting that TRAF2 has a nonredundant role in JNK activation but is redundant with TRAF5 with regard to IKK activation. Although the mechanisms underlying signal transduction from IKK to NF-nB and from MEKK1/3 to c-Jun are better understood, the receptor proximal events that trigger IKK versus MEKK1/3 activation by TRAF2 remain largely elusive.
In this study, we show that TRAF2 is phosphorylated on residue Ser 55 and that this modification has opposite effects on the prolonged phase of TNFa-induced IKK and JNK activation. In addition, we show that TRAF2 is constitutively phosphorylated at Ser 55 in some cancer cell lines and that this phosphorylation is significant for cancer cell resistance to stress-induced apoptosis.
introduced into the Flag-TRAF2 expression vector using the Quick Change site-directed mutagenesis kit (Stratagene) and confirmed by DNA sequencing. Retroviral vectors for the transduction of Flag-TRAF2 and Ha-Ras-V12 constructs were generated by subcloning the TRAF2 and Ha-Ras-V12 cDNAs into a pBabe-puro and pQCXIH-hygro plasmids, respectively.
[ 32 P]orthophosphate labeling and two-dimensional separation of phosphoamino acids. In vivo [ 32 P]orthophosphate labeling and twodimensional separation of amino acids on TLC plates were performed exactly as described previously (10) .
Preparation of retroviral supernatants and infection of TRAF2/5 DKO cells. TRAF2/5 DKO cells that stably express WT or phosphomutant TRAF2 were generated as described previously (10) .
Phosphoantibody were separated by SDS-PAGE and transferred onto nitrocellulose membranes. The blots were blocked with 0.2% Tween 20/TBS containing 3% bovine serum albumin for 4 h and incubated with TRAF2 phosphoantibody overnight at 4jC. The phosphorylation status of TRAF2 was then assessed using horseradish peroxidase-labeled secondary antibody and enhanced chemiluminescence solution. The same membranes were then stripped and reprobed with anti-TRAF2 antibody.
Real-time reverse transcription-PCR. TRAF2/5 DKO cells reconstituted with TRAF2-WT, TRAF2-S55A, or TRAF2-S55D were treated with mTNFa (10 ng/mL), and total RNA was prepared using the RNeasy mini kit (Qiagen). Real-time PCR assays for the quantification of NF-nBdependent gene expression were also performed exactly as described previously (10) .
Results

TRAF2 is phosphorylated at Ser
55 . In a previous study, we identified the Ser 11 residue of TRAF2 as one of the phosphorylation sites of the protein and developed a phosphospecific antibody (pTRAF2-Ser 11 ) that recognizes this modification (10) . In an in vivo [ 32 P]orthophosphate labeling experiment, coexpression of a constitutively active form of either PKCa or Akt1 (CA-PKCa and Myr-Akt1) with Flag-TRAF2 in NIH 3T3 cells increased overall TRAF2 phosphorylation (Fig. 1A) . However, Western blot analysis with pTRAF2-Ser 11 phosphoantibody revealed that coexpression of CA-PKCa or Myr-Akt1 with Flag-TRAF2 does not increase TRAF2 phosphorylation at Ser 11 in vivo ( Supplementary Fig. S1A ). Further analyses by in vivo [ 32 P]orthophosphate labeling approaches revealed that overexpression of either CA-PKCa or Myr-Akt1 with Flag-TRAF2, in which the Ser 11 residue is mutated to alanine (TRAF2-S11A), increases the phosphorylation of this mutant TRAF2 ( Supplementary Fig. S1B ), suggesting that PKCa and Akt1 induce TRAF2 phosphorylation at a different site.
To map the TRAF2 phosphorylation site modified by PKCa and Akt1, we first coexpressed Flag-TRAF2 with CA-PKCa and examined which type of phosphoamino acid is modified. To this end, we carried out two-dimensional separation of amino acids on a TLC plate after 32 P-labeled Flag-TRAF2 was hydrolyzed with 6 N HCl. As shown in Fig. 1B , both basal and inducible TRAF2 phosphorylation took place at serine residues. TRAF2 has been reported to be phosphorylated at Thr 117 (12) . However, we were not able to detect TRAF2 phosphorylation at threonine residues in NIH 3T3 cells. In a previous study, we had found that TRAF2 phosphorylation occurs primarily in the NH 2 terminal region between amino acids 1 and 128 (10) . As expected, an P-labeled Flag-TRAF2 was then immunoprecipitated, separated by SDS-PAGE, and transferred onto a polyvinylidene difluoride membrane. The membrane was exposed to X-ray film for 6 h and then probed with anti-Flag antibody. B, NIH 3T3 cells were cotransfected with Flag-TRAF2 (1.0 Ag) and pCDNA3 (1.0 Ag) or HA-CA-PKCa (0.5 Ag). 36 h after transfection, 32 P-labeled Flag-TRAF2 was purified and hydrolyzed in 6 N HCl. Hydrolyzed [ 32 P]Flag-TRAF2 was then separated on a TLC plate and exposed to X-ray film for 7 d. C, NIH 3T3 cells were cotransfected with the Flag-TRAF2-1-128-S11A mutant (1.0 Ag) and either HA-Myr-Akt1 (0.5 Ag) or HA-CA-PKCa (0.5 Ag) as indicated. 36 h after transfection, overall TRAF2 phosphorylation was detected as in A. D, WT and mutant forms of Flag-TRAF2-1-128-S11A were coexpressed with CA-PKCa in NIH 3T3 cells, and their phosphorylation was assessed as in A.
in vivo
32 P-labeling analysis revealed that CA-PKCa and Myr-Akt1 induce TRAF2 phosphorylation on the NH 2 terminal region at a site other than Ser 11 ( Fig. 1C) . Analysis of the TRAF2-1-128 amino acid sequence with the Scansite program revealed that serine residues 35, 55, 83, and 102 fit the consensus phosphorylation sites for PKC, Akt1, and CK1 (data not shown). We, thus, mutated each of these sites individually to alanine using the TRAF2-1-128-S11A plasmid as template and then coexpressed these mutants with CA-PKCa in NIH 3T3 cells.
32 P-labeling analysis revealed that mutation of Ser 55 to alanine significantly, but not completely, inhibits TRAF2-1-128-S11A phosphorylation, suggesting that Ser 55 is at least one target of PKCa (Fig. 1D ). In fact, Ser 55 (RYCS 55 F) is a consensus PKC phosphorylation site (RxxS/T, RxS/T, or S/TxR), as well as a consensus Akt1 phosphorylation site (RxxS/TF/L), and is conserved between mouse and human ( Supplementary Fig. S2B ). Notably, Ser 55 resides in the middle of the TRAF2 RING domain ( Supplementary Fig. S2A ).
TRAF2 Ser 55 phosphorylation increases NF-KB activation but inhibits c-Jun activation. To assess the role of TRAF2 phosphorylation in TNFa-induced c-Jun and NF-nB activation, we generated two phosphomutant TRAF2 plasmids: TRAF2-S55A (in which Ser 55 is mutated to alanine to abolish phosphorylation) and TRAF2-S55D (in which Ser 55 is mutated to aspartic acid to mimic phosphorylation). In luciferase reporter gene assays performed in WT MEFs, TRAF2-S55A expression reduced NF-nB activity by 20% to 30% but increased c-Jun activity by 20% to 30% compared with that measured in cells transfected with TRAF2-WT (Supplementary Fig. S3A and B). To examine the role of TRAF2 Ser 55 phosphorylation in the absence of interference from endogenous TRAF2 and TRAF5, we performed luciferase reporter gene assays in TRAF2/5 DKO MEFs. As shown in Fig. 2A and B, the expression of TRAF2-S55D significantly increased both the basal and inducible NF-nB activities compared with those measured in TRAF2-S55A-transfected cells, whereas the expression of TRAF2-S55A significantly increased basal c-Jun activity compared with that induced by TRAF2-WT and TRAF2-S55D expression. However, none of the constructs tested exhibited a dominant-negative effect to block TNFa-induced c-Jun and NF-nB activation. Overall, these findings suggest that TRAF2 phosphorylation at Ser 55 contributes to, but is not essential for, TNFa-induced activation of NF-nB and c-Jun.
TRAF2 Ser 55 phosphorylation has opposite effects on the prolonged phase of TNFA-induced IKK and JNK activation. To further examine the role of TRAF2 Ser 55 phosphorylation in TNFainduced JNK and IKK activation, we established TRAF2/5 DKO cell lines that stably express Flag-TRAF2-WT (pBa-T2-WT), Flag-TRAF2-S55A (pBa-T2-S55A), or Flag-TRAF2-S55D (pBa-T2-S55D) at physiologic levels as described previously (10) . Immunokinase assays revealed that stable expression of TRAF2-WT in TRAF2/5 DKO cells restores TNFa-induced transient, as well as secondary/ prolonged, IKK activation. However, stable expression of TRAF2-S55A restored the transient, but not the prolonged, phase of IKK activation (Fig. 2C , compare lanes 4 and 5 with lanes 9 and 10). Stable expression of TRAF2-S55D also altered the oscillation of IKK Figure 2 . TRAF2 Ser 55 phosphorylation increases NF-nB activity but decreases c-Jun activity. A and B, TRAF2/5 DKO MEFs were cotransfected with NF-nB-Luc or Jun2-Luc; pRL-TK and pCDNA3; TRAF2-WT, TRAF2-S55A, or TRAF2-S55D as indicated. 36 h after transfection, the cells were either mock-treated or treated with mTNFa (5 ng/mL) for 4 h, after which the NF-nB-Luc or Jun2-Luc activity was measured and normalized to pRL-TK activity. Columns, mean of three experiments that were done in triplicate; bars, SD. *, P < 0.05. C and D, TRAF2/5 DKO cells reconstituted with TRAF2-WT (pBa-T2-WT ), TRAF2-S55A (pBa-T2-S55A ), or TRAF2-S55D (pBa-T2-S55D ) were treated with mTNFa (10 ng/mL) for the indicated times (min). The IKK complex or JNK1 was immunoprecipitated with anti-IKKg or anti-JNK1 antibody, respectively, and subjected to in vitro kinase assays, in which GST-InBa 1-55 served as substrate for IKK and GST-Jun 1-87 served as substrate for JNK1. Reaction mixtures were separated by SDS-PAGE, transferred onto a nitrocellulose membrane, and exposed to X-ray film for 6 h ( 32 p-G-IjBa or 32 p-G-Jun). The same membrane was stained with Ponceau S (G-IjBa or G-Jun) and then immunoblotted with anti-IKKh or anti-JNK1 antibody (IKKb or JNK1 ).
activity after TNFa stimulation (Fig. 2C) . On the other hand, stable expression of TRAF2-S55A enhanced TNFa-induced prolonged JNK activation, although it had no effect on transient JNK activation (Fig. 2D, compare lanes 4 and 5 with lanes 9 and 10) . In vitro IKK and JNK kinase assays were repeated thrice, and average kinase activities are summarized in Supplementary Fig. S4A and B. Collectively, these data suggest that TRAF2 phosphorylation at Ser 55 positively regulates the prolonged phase of IKK activation while inhibiting the prolonged phase of JNK activation, which explains why TRAF2-S55A expression partially inhibits NF-nB activity and increases c-Jun activity.
TRAF2 Ser 55 phosphorylation is essential for the efficient expression of a subset of NF-nB target genes in response to TNFa stimulation. To examine the role of TRAF2 Ser 55 phosphorylation in TNFa-induced NF-nB activation in a physiological setting, we analyzed the expression of NF-nB target genes in pBa-T2-WT, pBa-T2-S55A, and pBa-T2-S55D cells by real-time reverse transcription-PCR. As shown in Fig. 3A and B, there were no significant differences in the expression levels of InBa and IP-10 in all three cell lines before and after TNFa stimulation. On the other hand, TNFa-induced expression of ICAM-1, RANTES, cIAP1, cIAP2, cFLIP, and Mn-SOD was significantly enhanced in pBa-T2-S55D cells compared with that in pBa-T2-S55A cells (Fig. 3C and D and Supplementary Fig. S5A-D) . In pBa-T2-WT cells, only ICAM-I and RANTES expression was significantly higher than that in pBa-T2-S55A cells. These data indicate that TRAF2 Ser . As shown in Supplementary Fig. S6A, pTRAF2 Fig. 4A , TNFa treatment immediately induced TRAF2 phosphorylation in HeLa cells with peak induction occurring 30 minutes after stimulation. We also examined TRAF2 phosphorylation in response to growth factors and various inducers of cellular stress. In addition to TNFa, UV strongly induced TRAF2 phosphorylation at Ser 55 in HeLa cells (Fig. 5B) . Unexpectedly, a potent activator of PKCa (TPA) only weakly induced TRAF2 Ser 55 phosphorylation, and a potent activator of Akt1 (IGF-I) did not induce TRAF2 Ser 55 phosphorylation at all in HeLa cells. These data suggest that although PKCa and Akt1 induce TRAF2 Ser 55 phosphorylation in transient overexpression system, they may not be involved in the phosphorylation of endogenous TRAF2.
TNFA-induced TRAF2 Ser 55 phosphorylation is mediated by PKCZ. To identify the kinases involved in TRAF2 phosphorylation at Ser 55 , we pretreated HeLa cells with various kinase inhibitors before stimulating them with TNFa. As shown in Supplementary  Fig. S7A , an inhibitor of both PKCa and PKC~(Go6983) significantly reduced TNFa-induced TRAF2 phosphorylation at Ser 55 but not at Ser 11 , whereas a PKCa-specific inhibitor (Go6976) failed to inhibit TRAF2 phosphorylation at either site. In line with this, PKC~-specific pseudosubstrates blocked TNFa-induced TRAF2 phosphorylation at Ser 55 but not at Ser 11 , whereas PKCa-specific Figure 3 . TRAF2 Ser 55 phosphorylation is essential for efficient TNFa-induced expression of a subset of NF-nB target genes. A-D, pBa-T2-WT, pBa-T2-S55A, and pBa-T2-S55D cells were treated with mTNFa (10 ng/mL) as indicated, and the expression levels of InBa, IP-10, ICAM-I, and cIAP1 were determined by real-time PCR. The relative expression level of each gene is presented as the ratio between it and the reference gene glyceraldehyde-3-phosphate dehydrogenase as an average from four independent experiments. *, P < 0.05.
pseudosubstrates did not block phosphorylation at either site (Fig. 4C) . These data suggest that PKC~is involved in TRAF2 phosphorylation at Ser 55 . To examine whether PKC directly phosphorylates TRAF2, we expressed and immunopurified HA-CA-PKCa, HA-CA-PKC~, and HA-Myr-Akt1 from 293T cells and used these preparations as kinase sources for an in vitro kinase assay in which bacterially expressed and purified GST-TRAF2-1-81 was used as a substrate. Interestingly, both PKCa and PKC~, but not Myr-Akt1, phosphorylated GST-TRAF2-1-81 (Fig. 4D) . Mutation of Ser 55 to alanine almost completely abolished PKC~-mediated TRAF2 phosphorylation in vitro (Supplementary Fig. S7B ). Collectively, these data suggest that PKC~directly phosphorylates TRAF2 at Ser 55 in response to TNFa stimulation. TRAF2 is constitutively phosphorylated in some cancer cell lines and in Hodgkin's lymphoma. NF-nB is constitutively activated in many types of human cancer cells (4). We, thus, wanted to determine whether TRAF2 phosphorylation is correlated with NF-nB activation in cancer cells. To this end, we examined the phosphorylation of TRAF2 in an assortment of wellestablished cancer cell lines: LNCaP and PC3 (prostate cancer), MDA-MB-231 (breast cancer), A549 (lung cancer), and WM1552, LU1205, FEMX, and THX (melanoma). As shown in Fig. 5A , TRAF2 was constitutively phosphorylated (but to varying degrees) in the PC3, MDA-231, A549, FEMX, and THX cell lines, and treatment of these cells with TNFa led to a further increase in TRAF2 Ser 55 phosphorylation. Consistently, inhibition of PKC~, but not of PKCa, with isotype-specific pseudosubstrate blocked constitutive phosphorylation of TRAF2 in A549 and THX cell lines (Fig. 5B) , suggesting that PKC~is responsible for basal TRAF2 Ser 55 phosphorylation in these cell lines. NF-nB is constitutively activated in Hodgkin's lymphoma and Hodgkin/ReedSternberg cell lines (13) . Thus, we also examined TRAF2 phosphorylation in Hodgkin's lymphoma tissues obtained from the Tissue Procurement Core Facility at the University of Iowa. As shown in Fig. 5C , TRAF2 was constitutively phosphorylated in five of six Hodgkin's lymphoma samples, but not in samples of normal tonsil and thyroid. These data show that constitutive TRAF2 phosphorylation is very common in both cancer cell lines and Hodgkin's lymphomas.
TRAF2 Ser 55 phosphorylation protects cells from stressinduced cell death. In TRAF2/5 DKO cells, TNFa stimulation causes the accumulation of reactive oxygen species and prolonged JNK activation, both of which ultimately lead to necrotic and apoptotic cell death (14) . We also observed that over 90% of TRAF2/5 DKO MEFs undergo cell death within 48 hours of TNFa treatment ( Supplementary Fig. S8A ). Notably, stable expression of TRAF2-WT, TRAF2-S55A, or TRAF2-S55D in TRAF2/5 DKO MEFs completely inhibited TNFa-induced cell death, indicating that the phosphorylation of TRAF2 is not required for its inhibition of TNFa-induced cell death. On the other hand, stable expression of TRAF2-S55D in TRAF2/5 DKO cells rendered cells more resistant to H 2 O 2 -induced cell death than did the expression of TRAF2-S55A (Fig. 6A) . However, we did not observe a significant difference between TRAF2-WT-transfected and TRAF2-S55A-transfected cells with respect to their sensitivity to H 2 O 2 -induced cell death. Colony formation assays (CFA) also revealed that pBa-T2-S55D cells are significantly more resistant to hydroxyurea-induced, etoposide-induced, and H 2 O 2 -induced apoptosis and/or growth arrest Figure 4 . TNFa-induced TRAF2 Ser 55 phosphorylation is mediated by PKC~. A and B, HeLa cells were left untreated or were treated with hTNFa, IGF-I, TPA, etoposide, hydroxyurea, camptothecin, or UV as indicated, and TRAF2 phosphorylation was monitored by Western blotting using TRAF2 phosphoantibodies. The same membranes were then stripped and reprobed with anti-TRAF2 or anti-h-actin antibody. C, HeLa cells were pretreated with myristoylated PKC isotype-specific pseudosubstrates (PS) for 60 min before being stimulated with hTNFa (20 ng/mL), and TRAF2 phosphorylation was then detected as in A. D, bacterially expressed and purified GST-TRAF2-1-81-WT (G-TRAF2-1-81) was subjected to an in vitro kinase assay in the presence of CA-PKCa, CA-PKC~, or Myr-Akt1 purified from 293T cells, and phosphorylation of TRAF2 was monitored as described in Fig. 2C .
than pBa-T2-S55A cells (Fig. 6B and Supplementary Fig. S8B ). To further assess the role of TRAF2 phosphorylation in the resistance of transformed cells to stress-induced cell death, we stably expressed Ha-Ras-V12 in pBa-T2-WT (T2-WT-Ras), pBa-T2-S55A (T2-S55A-Ras), and pBa-T2-S55D (T2-S55D-Ras) cells (Fig. 6C ) and then performed cytotoxicity and CFA assays. Interestingly, both the cytotoxicity and CFA assays revealed that T2-WT-Ras cells are significantly more resistant to stress-induced cell death than T2-S55A-Ras cells (Fig. 6D and Supplementary Fig. S9 ). These data suggest that TRAF2 phosphorylation at Ser 55 plays a critical role in protecting cells from stress-induced apoptosis.
Discussion
The PKC family of proteins is divided into three groups (15): conventional (including a, h, and g isotypes), novel (including D, q, y, and u isotypes), and atypical (including L/E and~isotypes). These PKCs possess broadly overlapping substrates and exhibit redundancy in their biological functions (16) (17) (18) . The phosphorylation of PKC substrates, in many cases, requires scaffold proteins (e.g., p62
for PKC~and RACK for PKCa), and these scaffold proteins are believed to regulate both the subcellular localization and substrate specificity of PKC isoforms in vivo (18, 19) . Several studies have shown that, whereas PKCa mediates TPA-induced NF-nB activation, PKC~mediates TNFa-induced NF-nB activation (16, 20, 21) . Thus, we speculated that PKCa may induce TRAF2 Ser 55 phosphorylation in response to TPA stimulation. However, TPA only weakly induced TRAF2 Ser 55 phosphorylation in all cell lines tested, including HeLa ( Fig. 4B ; data not shown). Thus, it is possible that, although transiently overexpressed CA-PKCa is able to induce TRAF2 Ser 55 phosphorylation, endogenous TRAF2 may not be a physiologic substrate for this kinase. Myr-Akt1 also increased TRAF2 phosphorylation in vivo (Fig. 1C) . However, an in vitro kinase assay revealed that Akt1 only weakly phosphorylates TRAF2 (Fig. 4D) , indicating that Akt1 may induce TRAF2 phosphorylation in vivo indirectly. One kinase can phosphorylate two or more substrates, and one protein can be phosphorylated by two or more kinases. Therefore, it is possible that TRAF2 can also be phosphorylated by other members of the PKC family or PKCrelated kinases.
An early study showed that PKC~directly activates IKK in response to TNFa stimulation (20) , and many subsequent studies have shown that inhibition of PKC~(by either a PKC~-specific pseudosubstrate or antisense oligonucleotides) significantly attenuates TNFa-induced expression of NF-nB target genes (such as MMP-9 and ICAM-I) in different cell types (16, 21, 22) . However, a more recent gene knockout study has shown that PKC~is not essential for TNFa-induced transient IKK activation but is required for efficient activation of the NF-nB pathway, both upstream and downstream of IKK (23) . The findings we present here show that PKC~-mediated TRAF2 phosphorylation at Ser 55 is not essential for TNFa-induced transient IKK activation but is required for the prolonged phase of IKK activation and that this phase plays an important role in the efficient expression of a subset of NF-nB target genes.
Our analysis of the expression of well-known NF-nB target genes in TRAF2/5 DKO cells reconstituted with TRAF2-WT or TRAF2-S55A revealed that TRAF2 Ser 55 phosphorylation is essential for the efficient expression of RANTES and ICAM-I, but not of InBa and IP-10, in response to TNFa stimulation (Fig. 3A-C and Supplementary Fig. S5A ). Expression of InBa and IP-10 was induced very quickly and peaked within 1 hour of TNFa stimulation, whereas the expression of RANTES and ICAM-1 rose relatively slowly. It seems that the transient activation of IKK that occurs in the absence of TRAF2 Ser 55 phosphorylation is sufficient to trigger efficient expression of IP-10 and InBa, but the prolonged phase of IKK activation regulated by TRAF2 Ser 55 phosphorylation is required for TNFa-induced expression of RANTES and ICAM-I. Thus, our data suggest that TRAF2 Ser 55 phosphorylation represents a new level at which this pathway controls the expression of a subset of NF-nB target genes by linking certain serine/threonine kinases to the prolonged phase of IKK activation.
TNFa-induced expression of antiapoptotic proteins, such as cIAP1/2, cFLIP, and Mn-SOD, was slightly reduced in TRAF2-S55A-expressing cells versus TRAF2-WT-expressing cells (Fig. 3C and Supplementary Fig. S5B-D) , although the differences were not statistically significant. A statistical difference with respect to inducible expression of these antiapoptotic proteins was observed only between TRAF-S55A-expressing and TRAF-S55D-expressing cells. Consistent with this finding, TRAF2-S55D-expressing cells, but not TRAF2-WT-expressing cells, displayed significantly elevated resistance to stress-induced apoptosis compared with TRAF2-S55A-expressing cells (Fig. 6A and B) . This suggests that the constitutive phosphorylation of TRAF2 plays a more important role than its inducible phosphorylation in protecting cells from stressinduced apoptosis.
The RING domain of TRAF2 has been reported to possess ubiquitin E3 ligase activity, and TRAF2-mediated RIP1 ubiquitination is currently thought to play an essential role in TNFa-induced IKK activation (24) . As the Ser 55 residue lies in the middle of the TRAF2 RING domain (Supplementary Fig. S2 ), we reasoned that TRAF2 Ser 55 phosphorylation may affect TRAF2 E3 ligase activity. However, we did not observe any difference between TRAF2-WT-expressing and TRAF2-S55A-expressing cells with respect to TRAF2 self-ubiquitination or RIP1 ubiquitination ( Supplementary  Fig. S10A and B) .
The proapoptotic protein Par-4 interacts with and inhibits the kinase activity of PKC~ (16) . Genetic inactivation of Par-4 results in elevated NF-nB but decreased JNK activation in response to TNFa stimulation (16) . This correlates very well with PKC~-mediated phosphorylation of TRAF2 at Ser 55 and with the role of this phosphorylation in TNFa-induced IKK and JNK activation. In Ras-transformed cells, the Par-4 protein level is down-regulated, and restoration of Par-4 levels to normal in Ras-transformed cells makes these cells sensitive to camptothecin-induced apoptosis (25) . Consistent with this finding, the expression of TRAF2-S55A in Ras-transformed TRAF2/5 DKO cells strongly sensitized cells to stress-induced cell death (Fig. 6D) . PKC~is highly expressed and constitutively activated in many types of human cancer cells (16, 25, 26) . In the study presented here, we showed that TRAF2 is constitutively phosphorylated at Ser 55 in several malignant cancer cell lines, as well as in Hodgkin's lymphoma ( Fig. 5A and B) . Therefore, our data and findings that have been published by others suggest that elevated PKC~activation and the consequent increase in TRAF2 Ser 55 phosphorylation are one of the causes of the elevated NF-nB activation in cancer cells therein, as well as of the resistance of cancer cells to stressinduced apoptosis.
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